🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

437,23 USD

Máx. histórico

447,03

10 días

Caída desde máximo

-2,19%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-1,55%

Cierre anterior

444,12

Rango de hoy

435,01 – 441,66

Volumen hoy

1.615.172

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER
27,17 (puede no estar actualizado)
Dividend yield
2,27% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 2 días
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,27%
Fecha de pago Importe por participación
16/11/2022 1,9400 USD
17/08/2022 1,9400 USD
16/05/2022 1,9400 USD
14/02/2022 1,9400 USD
15/11/2021 1,7600 USD
16/08/2021 1,7600 USD
14/05/2021 1,7600 USD
11/02/2021 1,7600 USD
13/11/2020 1,6000 USD
14/08/2020 1,6000 USD
15/05/2020 1,6000 USD
13/02/2020 1,6000 USD
14/11/2019 1,4500 USD
14/08/2019 1,4500 USD
16/05/2019 1,4500 USD
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
22/01/2016 156,45 156,96 154,24 156,08 +2,16% 1,74% 4.577.300
21/01/2016 154,75 155,02 150,24 152,78 -1,44% 3,09% 4.674.000
20/01/2016 149,00 156,84 148,05 155,02 +2,46% 5,90% 7.338.600
19/01/2016 153,45 154,62 148,23 151,30 +0,00% 4,16% 4.382.200
15/01/2016 147,69 152,30 147,69 151,30 -1,21% 3,12% 6.213.000
14/01/2016 146,02 155,30 144,57 153,16 +5,29% 7,35% 5.649.000
13/01/2016 151,14 152,83 145,28 145,46 -3,53% 5,00% 3.982.100
12/01/2016 148,43 151,24 146,92 150,79 +2,10% 2,91% 4.410.600
11/01/2016 151,33 151,59 144,17 147,69 -2,00% 4,90% 4.747.400
08/01/2016 153,12 154,86 150,46 150,71 -1,48% 2,87% 4.179.600
07/01/2016 153,06 156,45 152,89 152,98 -2,39% 2,33% 4.162.500
06/01/2016 155,01 157,93 154,90 156,72 -0,92% 1,95% 3.826.900
05/01/2016 159,00 160,21 157,25 158,17 -0,11% 1,86% 2.678.900
04/01/2016 159,00 159,22 156,09 158,34 -2,46% 1,97% 5.083.200
31/12/2015 162,15 164,11 162,05 162,33 -0,59% 1,27% 1.775.900
30/12/2015 164,63 164,75 162,91 163,29 -0,70% 1,12% 1.493.000
29/12/2015 162,92 164,96 162,05 164,44 +1,68% 1,79% 2.171.100
28/12/2015 162,91 163,13 160,60 161,73 -1,11% 1,55% 1.513.000
24/12/2015 163,70 164,36 162,22 163,55 +0,51% 1,31% 943.000
23/12/2015 163,03 163,50 161,65 162,72 +0,26% 1,13% 2.202.100
22/12/2015 160,50 163,37 160,04 162,30 +1,90% 2,07% 3.125.500
21/12/2015 159,88 160,38 157,38 159,28 +0,30% 1,88% 3.818.900
18/12/2015 160,50 161,82 158,62 158,80 -1,63% 1,99% 6.227.000
17/12/2015 164,58 164,99 159,81 161,43 -1,91% 3,15% 3.699.400
16/12/2015 164,31 165,23 162,10 164,58 +1,21% 1,90% 3.923.600
15/12/2015 161,65 164,45 161,56 162,62 +2,85% 1,79% 5.365.600
14/12/2015 155,98 158,34 153,43 158,11 +1,91% 3,15% 2.780.600
11/12/2015 157,82 158,78 154,79 155,15 -2,83% 2,53% 3.005.700
10/12/2015 158,97 160,85 157,00 159,67 +1,13% 2,42% 2.814.000
09/12/2015 158,35 159,81 156,12 157,89 -0,92% 2,33% 2.995.600